Detail akcie Insulet online

Business Summary: Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Insulet Corp revenues increased 29% to $569M. Net income decreased 31% to $35.4M. Revenues reflect Omnipod System segment increase of 26% to $401.7M, International Omnipod segment increase of 32% to $152.4M. Net income was offset by Selling, general and administrative exp. increase of 20% to $226M (expense), Research and development expenses increase of 19% to $57M (expense).